Allergosan 5mg 20 tablets — Made in Bulgaria — Free Delivery

Product description

Allergozan® tablets are prescribed for adults and children over 12 years of age to relieve symptoms associated with:

• allergic rhinitis;
• hives.

Structure

The active ingredient is desloratadine (one tablet contains 5 mg desloratadine).

Excipients: microcrystalline cellulose, calcium hydrogen phosphate dihydrate, corn starch, hypromellose, talc, sodium stearyl fumarate, colloidal anhydrous silicon dioxide; film coating: Opadry II 33G 205005 blue (hypromellose, lactose monohydrate, titanium dioxide (E 171), macrogol 3350, triacetin, indigo carmine aluminum varnish (E 132), quinoline yellow aluminum varnish (E 104)).

Contraindications

Hypersensitivity to the active substance or to any of the excipients of the preparation or to loratadine.

Mode of application

Take orally with or without food.

Adults and children over 12 years of age: it is recommended one tablet once a day, regardless of food intake, to eliminate symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.

Intermittent allergic rhinitis therapy (the presence of symptoms less than 4 days a week or less than 4 weeks) should be carried out taking into account the history data: stop after the symptoms disappear and restore after their reappearance.

With persistent allergic rhinitis (the presence of symptoms more than 4 days a week or more than 4 weeks), it is necessary to continue treatment during the entire period of contact with the allergen.

Application features

Pregnant

Desloratadine has not been shown to be teratogenic in animal studies. The safety of using the preparation during pregnancy has not been established, therefore, the use of desloratadine during this period is not recommended.

Desloratadine passes into breast milk, so its use in women who are breastfeeding is not recommended.

Children

There are limited data from clinical studies of the effectiveness of desloratadine in adolescents aged 12 to 17 years.

There is no established data on the efficacy and safety of using desloratadine in children under 12 years of age.

Drivers

In clinical studies, during which the ability to drive vehicles was assessed, no deterioration was found in patients taking desloratadine. However, patients should be advised that very rarely some people experience drowsiness, which can affect their ability to drive a car and complex equipment.

Overdose

In case of overdose, adverse reactions are similar to those observed at therapeutic doses, but the manifestations may be stronger.

Symptoms In clinical studies in which desloratadine was administered in doses up to 45 mg (which is 9 times higher than recommended), clinically significant adverse reactions were not observed.

Treatment. In case of overdose, standard measures should be taken to remove the non-adsorbed active substance. Symptomatic and supportive treatment is recommended. Desloratadine is not removed by hemodialysis; the possibility of its removal during peritoneal dialysis has not been established.

Side effects

The most common adverse reactions reported compared to placebo were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 2 years.